Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome

Cutaneous-skeletal hypophosphatemia syndrome (CSHS) is a rare bone disorder featuring fibroblast growth factor-23 (FGF23)-mediated hypophosphatemic rickets. We report a 2-year, 10-month-old girl with CSHS treated with burosumab, a novel human monoclonal antibody targeting FGF23. This approach was as...

Full description

Bibliographic Details
Published in:Bone Reports
Main Authors: Lillian Abebe, Kim Phung, Marie-Eve Robinson, Richelle Waldner, Sasha Carsen, Kevin Smit, Andrew Tice, Joanna Lazier, Christine Armour, Marika Page, Saunya Dover, Frank Rauch, Khaldoun Koujok, Leanne M. Ward
Format: Article
Language:English
Published: Elsevier 2024-03-01
Subjects:
Cutaneous-skeletal hypophosphatemia syndrome
Fibroblast growth factor-23
Hypophosphatemic rickets
Burosumab
Conventional treatment
Child
Online Access:http://www.sciencedirect.com/science/article/pii/S2352187223000712

Internet

http://www.sciencedirect.com/science/article/pii/S2352187223000712

Similar Items